Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D, Ölmez ÖF, Sümbül AT, Özhan N, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S, Artaç M. Tural D, et al. Among authors: olmez of. Int J Clin Oncol. 2021 Aug;26(8):1506-1513. doi: 10.1007/s10147-021-01936-6. Epub 2021 May 23. Int J Clin Oncol. 2021. PMID: 34023933
GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients.
Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. Peled N, et al. Among authors: olmez of. Lung Cancer. 2020 Oct;148:48-54. doi: 10.1016/j.lungcan.2020.07.022. Epub 2020 Jul 27. Lung Cancer. 2020. PMID: 32799090
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Tural D, et al. Among authors: olmez of. Eur Urol Focus. 2021 Sep;7(5):1061-1066. doi: 10.1016/j.euf.2020.09.010. Epub 2020 Sep 30. Eur Urol Focus. 2021. PMID: 33008789
The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study.
Akdeniz N, Kaplan MA, Uncu D, İnanç M, Kaya S, Dane F, Küçüköner M, Demirci A, Bilici M, Durnalı AG, Koral L, Şendur MAN, Erol C, Türkmen E, Ölmez ÖF, Açıkgöz Ö, Laçin Ş, Şahinli H, Urakçı Z, Işıkdoğan A. Akdeniz N, et al. Among authors: olmez of. Int J Colorectal Dis. 2021 Jun;36(6):1311-1319. doi: 10.1007/s00384-021-03888-9. Epub 2021 Feb 14. Int J Colorectal Dis. 2021. PMID: 33586012
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study.
Bilici A, Uysal M, Menekse S, Akin S, Yildiz F, Turan M, Sezgin Goksu S, Beypinar I, Sakalar T, Değirmenci M, Erdem D, Basaran G, Olmez OF, Avci N, Tural D, Sakin A, Turker S, Demir A, Temiz S, Kaplan MA, Dogan M, Tanriverdi O, Bilgetekin I, Cinkir HY, Acikgoz O, Paydas S, Uslu R, Turhal S. Bilici A, et al. Among authors: olmez of. Cancer Invest. 2022 Feb;40(2):199-209. doi: 10.1080/07357907.2021.2017952. Epub 2021 Dec 22. Cancer Invest. 2022. PMID: 34894960
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
Gürbüz M, Kutlu Y, Akkuş E, Köksoy EB, Köse N, Öven BB, Uluç BO, Demiray AG, Erdem D, Demir B, Turhal NS, Üskent N, Akbaş S, Selçukbiricik F, İnal A, Bilici A, Ölmez ÖF, Çabuk D, Ünal Ç, Hızal M, Şendur MAN, Korkmaz M, Karadurmuş N, Ertürk İ, Göksu SS, Tatlı AM, Güven DC, Kılıçkap S, Paksoy N, Aydıner A, Çınkır HY, Özkul Ö, Öztürk A, Ballı S, Kemal Y, Erdoğan AP, Er Ö, Yumuk PF, Demirkazık A. Gürbüz M, et al. Among authors: olmez of. J Cancer Res Clin Oncol. 2022 Dec;148(12):3547-3555. doi: 10.1007/s00432-022-04087-x. Epub 2022 Jun 11. J Cancer Res Clin Oncol. 2022. PMID: 35689097
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer.
Goktas Aydin S, Cakan Demirel B, Bilici A, Topcu A, Aykan MB, Kahraman S, Akbıyık I, Atci MM, Olmez OF, Yaren A, Sendur MAN, Geredeli C, Seker M, Urun Y, Karadurmus N, Aydin A. Goktas Aydin S, et al. Among authors: olmez of. Curr Med Res Opin. 2022 Oct;38(10):1751-1758. doi: 10.1080/03007995.2022.2108619. Epub 2022 Aug 16. Curr Med Res Opin. 2022. PMID: 35916475
58 results